A placebo-controlled trial of the addition of the NRTI alovudine (at doses of 2 mg or less per day) to HAART in highly treatment-experienced patients with detectable viral loads (VL)
ANTIVIRAL THERAPY（2005）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要